UNH’s 86.7% MCR had an $860M asterisk — plus Axon and Gartner still live Aug 4

Not everything on the August 4 tape is chips and racks — and not every clean headline number survives contact with its own press release. The example this week: UnitedHealth’s much-quoted 86.7% medical care ratio came with $860M of net favorable prior-period development attached, a footnote most recaps skipped. This checklist digests UNH (already reported July 16) and previews Axon and Gartner, the adjacent names still live in the window. Royal Caribbean printed July 28; noted only as calendar spillover from the same ticker batch.

This is research, not investment advice — if you want tips, wrong page. Figures from SEC Exhibit 99.1 filings.

Who prints when

Ticker	Status	Last filed checkpoint
UNH	Already Jul 16	Q2 Ex 99.1 — digest below
AXON	~Aug 4	Q1 Ex 99.1 (May 6)
IT	~Aug 4	Q1 Ex 99.1 (May 5)
RCL	Already Jul 28	Travel adjacent — skip for thesis

UnitedHealth — Q2 already on file (digest, not preview)

Q2 2026 Exhibit 99.1 (Jul 16; accession 0000731766-26-000191, CIK 0000731766):

Line	Amount
Revenue	$112.0B
Earnings from operations	$8.0B
EPS / adjusted EPS	$6.04 / $6.38
Medical care ratio (MCR)	86.7% (vs 89.4% YoY)
UHC people served	48.5M (−525k sequential)
UHC revenue / op. earnings	$86.0B / $3.9B (op. margin 4.6%)
Optum revenue / earnings	$65.7B / $4.0B (+160 bps margin YoY)
FY26 diluted EPS outlook	$18.45–$18.95
FY26 adjusted EPS outlook	$19.50–$20.00
FY26 MCR outlook	88.1% ± 25 bps

The asterisk on the headline: the 86.7% MCR was affected by $860M of net favorable prior-period reserve development, the majority of it related to 2026 dates of service. Strip the framing and the read changes — a chunk of the 270-bp YoY MCR improvement is reserve trueup, not purely underlying cost trend. That is exactly why the company still guides FY26 MCR to 88.1% ± 25 bps, well above the Q2 print.

Optum Health detail worth keeping: Q2 revenue $23.5B (−5% YoY) on ~700k fewer value-based-care patients — progress on cost management with a membership headwind.

Residual watch (post-print): underlying medical cost trend once the $860M development washes out, Medicare Advantage / Medicaid mix, whether the raised adj. EPS band holds into Q3, and Optum Insight AI product conversion after the Alegeus close.

Axon — Q1 baseline into the Aug 4 print

Q1 2026 Exhibit 99.1 (May 6; CIK 0001069183):

Line	Amount
Revenue	$807M (+34% YoY)
Software & Services	$355M (+35%)
ARR	$1.5B (+35%)
NRR	125%
AI products	+700% YoY
Counter-drone	+300% YoY
FY revenue growth outlook (raised)	30–32%
Adj. EBITDA margin frame	~25.5%

Q1 marked the ninth consecutive quarter of 30%+ revenue growth — the streak is the thing Tuesday either extends to ten or breaks. Axon is public-safety / software-adjacent, not hospital MCR — different risk set than UNH, same “budget execution” tape.

Aug 4 scorecard: (1) reaffirm or raise the 30–32% growth band, (2) software mix vs. devices, (3) ARR / NRR 125% hold, (4) AI and counter-drone still compounding off a small base, (5) FCF vs. growth spend.

Gartner — enterprise spend proxy on the same day

Q1 2026 Exhibit 99.1 (May 5; accession 0000749251-26-000165, CIK 0000749251):

Line	Amount
Contract value	$5.3B (+1.0% YoY FX-neutral)
Revenues	$1.511B (−1.5% reported / −4.3% FX-neutral)
Adjusted EPS	$3.32
Share repurchases (quarter)	$535M
Buyback authorization	Board added $600M in April 2026

Read that table honestly: revenue is shrinking (−1.5% reported, −4.3% FX-neutral) while adjusted EPS grows — the gap is buybacks and cost discipline, not demand. Contract value barely positive at +1.0% FX-neutral is the forward-demand tell for enterprise tech budgets (including healthcare IT). Gartner is research & advisory, not a care-delivery name.

Aug 4 scorecard: contract value re-acceleration or continued stall; whether revenue decline narrows; retention; H2 guide; Research vs. Conferences mix; pace of the fresh $600M buyback authorization.

Royal Caribbean — calendar only

RCL Q2 (Jul 28): revenue $4.8B (+6%); load factor 110%; FY revenue growth guide ~9%. Travel, not healthcare — drop from this thesis.

One scoreboard

UNH (done) — 86.7% MCR minus the $860M development, and the $19.50–$20.00 adj. EPS band, are the real bars.
AXON (live) — extend the 30%+ streak to a tenth quarter with software/ARR quality.
IT (live) — contract value as the enterprise-budget tell; watch whether EPS growth keeps outrunning shrinking revenue.
Do not confuse insurer underwriting (UNH) with public-safety software (AXON) or research wallets (IT) — same week, different models.

Headlines quoted the MCR; the filing sized the reserve release. Live multiples: UNH · AXON · IT · RCL.

Primary sources

UNH Q2 Ex 99.1 (Jul 16): https://www.sec.gov/Archives/edgar/data/731766/000073176626000191/ (0000731766-26-000191).

AXON Q1 Ex 99.1: accession family May 6, 2026 (axon-20260506xex991), CIK 0001069183.

IT Q1 Ex 99.1: https://www.sec.gov/Archives/edgar/data/749251/000074925126000165/ (0000749251-26-000165).

First step: open UNH’s Q2 release and find the prior-period development sentence — one number, $860M, and you’ll read every MCR headline this quarter differently.

Research, not investment advice.